| Oncology | Lifetime | 30 | US 17 | 99.95 |
| Cancer Research | Lifetime | 22 | US 15 | 99.85 |
| Pulmonary and Respiratory Medicine | Lifetime | 356 | US 195 | 99.56 |
| Genetics | Lifetime | 756 | US 390 | 98.15 |
| Oncology | 2021-2025 | 76 | US 32 | 99.56 |
| Cancer Research | 2021-2025 | 61 | US 19 | 97.21 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 276 | US 86 | 97.57 |
| Public, Environmental and Occupational Health | 2021-2025 | 972 | US 345 | 89.82 |
| Cancer Treatment and Pharmacology | Lifetime | 7 | US 4 | 99.95 |
| Advanced Breast Cancer Therapies | Lifetime | 3 | US 2 | 99.94 |
| Breast Cancer Treatment Studies | Lifetime | 8 | US 3 | 99.95 |
| HER2/EGFR in Cancer Research | Lifetime | 6 | US 3 | 99.94 |
| BRCA gene mutations in cancer | Lifetime | 45 | US 25 | 99.39 |
| Brain Metastases and Treatment | Lifetime | 50 | US 37 | 99.48 |
| Cancer Genomics and Diagnostics | Lifetime | 212 | US 134 | 99.54 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 295 | US 166 | 99.28 |
| Global Cancer Incidence and Screening | Lifetime | 148 | US 76 | 99.01 |
| Lung Cancer Treatments and Mutations | Lifetime | 440 | US 215 | 98.99 |
| Estrogen and related hormone effects | Lifetime | 300 | US 191 | 98.78 |
| Cancer survivorship and care | Lifetime | 175 | US 95 | 98.61 |
| Peptidase Inhibition and Analysis | Lifetime | 430 | US 202 | 98.40 |
| Economic and Financial Impacts of Cancer | Lifetime | 130 | US 87 | 98.14 |
| Cancer Risks and Factors | Lifetime | 233 | US 120 | 98.31 |
| PARP inhibition in cancer therapy | Lifetime | 212 | US 109 | 97.13 |
| Cancer-related cognitive impairment studies | Lifetime | 107 | US 77 | 97.23 |
| Cancer Cells and Metastasis | Lifetime | 740 | US 327 | 97.13 |
| Lung Cancer Research Studies | Lifetime | 653 | US 281 | 97.79 |
| Breast Lesions and Carcinomas | Lifetime | 431 | US 203 | 97.07 |
| Male Breast Health Studies | Lifetime | 33 | US 17 | 93.89 |
| Breast Implant and Reconstruction | Lifetime | 553 | US 293 | 94.43 |
| Family Support in Illness | Lifetime | 868 | US 403 | 93.38 |
| Ethics in Clinical Research | Lifetime | 738 | US 389 | 91.29 |
| HER2/EGFR in Cancer Research | 2021-2025 | 35 | US 14 | 99.32 |
| Breast Cancer Treatment Studies | 2021-2025 | 56 | US 22 | 99.16 |
| Advanced Breast Cancer Therapies | 2021-2025 | 60 | US 25 | 98.96 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 408 | US 159 | 98.41 |
| Brain Metastases and Treatment | 2021-2025 | 85 | US 49 | 96.66 |
| Cancer Genomics and Diagnostics | 2021-2025 | 434 | US 201 | 97.11 |
| Cancer Treatment and Pharmacology | 2021-2025 | 167 | US 53 | 96.81 |
| BRCA gene mutations in cancer | 2021-2025 | 203 | US 95 | 93.51 |
| Cancer Risks and Factors | 2021-2025 | 254 | US 99 | 89.20 |
| Estrogen and related hormone effects | 2021-2025 | 463 | US 155 | 80.47 |
| Male Breast Health Studies | 2021-2025 | 32 | US 18 | 82.70 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 563 | US 197 | 74.90 |
| Cancer, Stress, Anesthesia, and Immune Response | 2021-2025 | 865 | US 216 | 58.63 |
